ZSP1273 600 mg

DRUG2 trials

Sponsors

Guangdong Zhongsheng Pharmaceutical Co., Ltd., Guangdong Raynovent Biotech Co., Ltd

Conditions

InfluenzaInfluenza A

Phase 1

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

CompletedNCT03679143

Guangdong Zhongsheng Pharmaceutical Co., Ltd.Influenza

Start: 2018-09-20End: 2019-04-26Updated: 2019-08-14

Phase 3

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

CompletedNCT04683406

Guangdong Raynovent Biotech Co., LtdInfluenza A

Start: 2020-12-28End: 2023-05-16Updated: 2023-06-27

Related Papers

Onradivir: First Approval.

2025-09-25

Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial.

2025-06-072 citations

A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug–drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects

Antimicrobial Agents and Chemotherapy2025-02-245 citations

Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects

Expert Opinion on Investigational Drugs2021-10-1717 citations